<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kleindorfer, Dawn</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Eligibility for rt-PA within a Population: The Effect of the ECASS-3 Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">According to standard emergency department (ED) guidelines, ischemic stroke patients must present to an ED within &lt;3 hours of symptom onset to be eligible for rt-PA therapy. The European Cooperative Acute Stroke Study-3 [ECASS-3] expanded this eligibility window to 4.5 hours but with additional exclusion criteria. Even with this expanded time window, eligibility for rt-PA remains low—about 9% versus 8% for the older time window.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>